Progress in the Application of Direct Oral Anticoagulants in Pediatric Patients
LIU Fang1,2, TANG Xiao-wan1, ZHENG Yue-hong3, MEI Dan1, DU Li-ping1*
1. Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China; 2. Depatment of Pharmacy,Beijing Luhe Hospital Affiliated to Capital University of Medical Sciences, Beijing 100069, China; 3. Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Abstract：Compared with the traditional oral anticoagulant warfarin, the new oral anticoagulants,also called direct oral anticoagulants,have the advantages of fast onset, short half-life, less interactions with food and drugs, and no need to frequently monitor coagulation indicators. With the increasing demand for anticoagulants in children,direct oral anticoagulants show great potential in the field of pediatrics. This paper reviews the latest guidelines and the research progress of new oral anticoagulants in children in order to provide help for the selection of anticoagulant drugs for children in China.
刘芳, 唐筱婉, 郑月宏, 梅丹, 都丽萍. 直接口服抗凝药在儿童患者中的应用进展[J]. 中国药学杂志, 2022, 57(16): 1323-1328.
LIU Fang, TANG Xiao-wan, ZHENG Yue-hong, MEI Dan, DU Li-ping. Progress in the Application of Direct Oral Anticoagulants in Pediatric Patients. Chinese Pharmaceutical Journal, 2022, 57(16): 1323-1328.
CHAR W,LESLIE R. Treatment of venous thromboembolism in pediatric patients[J]. Blood, 2020,135(5): 335-343.
[2]
PAUL M,ELIZABETH C,ANTHONY C,et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines.[J]. Chest, 2012.141(Suppl 2):e737S-e801S.
[3]
ROSSANO J W, CABRERA A G, JEFFERIES J L, et al. Pediatric cardiac intensive care society 2014 consensus statement[J]. Pediatr Crit Care Med, 2016, 17:S20-S34.
[4]
MAHAJERIN A, PETTY J K, HANSON S J, et al. Prophylaxis against venous thromboembolism in pediatric trauma: A practice management guideline from the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society[J].J Trauma Acute Care Surg, 2017, 82(3):627-636.
[5]
American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism[J]. Blood Adv, 2018,2(22):3292-3316.
[6]
MORGAN J, CHECKETTS M, ARANA A, et al. Prevention of perioperative venous thromboembolism in pediatric patients: Guidelines from the Association of PaediatricAnaesthetists of Great Britain and Ireland(APAGBI)[J]. Pediatric Anesthesia, 2018, 28(5):382-391.
[7]
SIBSON K R, BISS T T, FURNESS C L, et al. BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy[J]. Br J Haematol, 2018, 180(4):511-525.
[8]
HALTON J M L, ALBISETTI M, BISS B, et al. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability[J]. J Thromb Haemost, 2017, 15(11):2147-2157. doi: 10.1111/jth.13847.
[9]
HALTON J M L, PICARD A C, HARPER R, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism[J]. Thromb Haemost, 2017, 117(11): 2168-2175.
[10]
HALTON J, BRANDÃO L R, LUCIANI M, et al.Dabigatran etexilate for the treatment of acute venous thromboembolism in children(DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial[J]. Lancet Haematol, 2021, 8(1):e22-e33.
[11]
ALBISETTI M,BRANDAO L, BOMGAARS L, et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients-results of the DIVERSITY trial[J]. Res Pract Thromb Haemost, 2019,03(S1):139-140.
[12]
LEONARDO R, BRAND O, MANUELA A, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children[J]. Blood, 2020,135(7):491-504.
[13]
European Medicines Agency. Committee for medicinal products for human use(CHMP). Minutes for the meeting on 09-12 November 2020. Pradaxa - dabigatran etexilate - EMEA/H/C/000829/X/0122/G[EB/OL]. https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-9-12-november-2020_en.pdf[2021-01-05](2021.3.23)
[14]
MALE C, LENSING A W A, PALUMBO J S, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial[J]. Lancet Haematol, 2020,7(1):e18-e27.
[15]
MONAGLEP, LENSING A W A, THELEN K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism(EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies[J]. Lancet Haematol, 2019,6(10):e500-e509.
[16]
MALE C, LENSING A W A, PALUMBO J S. EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial[J]. Lancet Haematol, 2020, 7(1):e18-e27.
[17]
European Medicines Agency. European Medicines Agency decision [EB/OL]. [2019-04-17]. https://www.ema.europa.eu/en/documents/pip-decision/p/0126/2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan_ en.pdf.
[18]
Center For Drug Evaluation,NMPA. Publicity of drug priority review. Acceptance No: JXHS2000148/9 [EB/OL]. [2021-03-23]. http://www.cde.org.cn/news.do?method= changePage&pageName=service&frameStr=21#
[19]
Daiichi Sankyo, Inc.Edoxaban for prevention of blood vessels being vlocked by clots(thrombotic events) in children at risk because of cardiac disease[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT03395639.
[20]
SankyoDaiichi,Inc. Hokusai study in pediatric patients withconfirmed venous thromboembolism(VTE)[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT02798471.
[21]
VANOMMEN C H, ALBISETTI M, CHAN A K, et al. The Edoxaban Hokusai VTE pediatricsstudy: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease[J]. Res Pract Thromb Haemost, 2020,4(5):886-892. Doi:10.1002/rth2.12352.
[22]
Bristol-Myers Squibb,A study of the safety and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with asparaginase[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT02369653.
[23]
New York Medical College. Oral anticoagulant apixaban for treatment of venous thromboembolism(VTE)[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT04041843.
[24]
Pfizer, Apixaban for the acute treatment of venous thromboembolism in children[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT02464969
[25]
Food and Drug Administration. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients [EB/OL]. [2017-10-26]. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm.
[26]
MONAGLE P,CUELLO C A,AUGUSTINE C,et al. American Society of Hematology 2018 guidelinesfor management of venous thromboembolism:treatment of pediatric venous thromboembolism[J]. Blood Adv,2018,2(22):3292-3316.
[27]
MAHAJERIN A,CROTEAU S E. Epidemiology and risk assessment of pediatric venous thromboembolism [J]. Front Pediatr,2017, Doi: 10.3389/fped.2017.00068.
[28]
GOLDENBERG N A, KITTELSON J M, ABSHIRE T C, et al. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism the Kids-DOTT randomized clinical trial[J]. JAMA,2022,327(2):129-137.
2022, Vol. 57 
